397 related articles for article (PubMed ID: 29808317)
1. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of breast cancer invasion by TIS21/BTG2/Pc3-Akt1-Sp1-Nox4 pathway targeting actin nucleators, mDia genes.
Choi JA; Jung YS; Kim JY; Kim HM; Lim IK
Oncogene; 2016 Jan; 35(1):83-93. PubMed ID: 25798836
[TBL] [Abstract][Full Text] [Related]
3. Translational downregulation of Twist1 expression by antiproliferative gene, B-cell translocation gene 2, in the triple negative breast cancer cells.
Devanand P; Sundaramoorthy S; Ryu MS; Jayabalan AK; Ohn T; Lim IK
Cell Death Dis; 2019 May; 10(6):410. PubMed ID: 31138781
[TBL] [Abstract][Full Text] [Related]
4. Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
Jhanwar-Uniyal M; Amin AG; Cooper JB; Das K; Schmidt MH; Murali R
Adv Biol Regul; 2017 May; 64():39-48. PubMed ID: 28189457
[TBL] [Abstract][Full Text] [Related]
5. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
6. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
7. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.
Morrison Joly M; Hicks DJ; Jones B; Sanchez V; Estrada MV; Young C; Williams M; Rexer BN; Sarbassov dos D; Muller WJ; Brantley-Sieders D; Cook RS
Cancer Res; 2016 Aug; 76(16):4752-64. PubMed ID: 27197158
[TBL] [Abstract][Full Text] [Related]
8. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
9. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
Razmara M; Monazzam A; Skogseid B
Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
[TBL] [Abstract][Full Text] [Related]
10. TIS21/(BTG2) negatively regulates estradiol-stimulated expansion of hematopoietic stem cells by derepressing Akt phosphorylation and inhibiting mTOR signal transduction.
Kim BC; Ryu MS; Oh SP; Lim IK
Stem Cells; 2008 Sep; 26(9):2339-48. PubMed ID: 18556508
[TBL] [Abstract][Full Text] [Related]
11. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of TNFα-interacting protein α (Tipα)-associated gastric carcinogenesis by BTG2
Devanand P; Oya Y; Sundaramoorthy S; Song KY; Watanabe T; Kobayashi Y; Shimizu Y; Hong SA; Suganuma M; Lim IK
Exp Mol Med; 2018 Feb; 50(2):e449. PubMed ID: 29472702
[TBL] [Abstract][Full Text] [Related]
13. Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR.
Cuesta R; Gritsenko MA; Petyuk VA; Shukla AK; Tsai CF; Liu T; McDermott JE; Holz MK
Mol Cell Proteomics; 2019 Aug; 18(8):1607-1618. PubMed ID: 31189691
[TBL] [Abstract][Full Text] [Related]
14. TIS21(/BTG2/PC3) inhibits interleukin-6 expression via downregulation of STAT3 pathway.
Quy LN; Choi YW; Kim YH; Chwae YJ; Park TJ; Lim IK
Cell Signal; 2013 Dec; 25(12):2391-9. PubMed ID: 23917204
[TBL] [Abstract][Full Text] [Related]
15. Regulation of Btg2(/TIS21/PC3) expression via reactive oxygen species-protein kinase C-ΝFκΒ pathway under stress conditions.
Imran M; Lim IK
Cell Signal; 2013 Dec; 25(12):2400-12. PubMed ID: 23876794
[TBL] [Abstract][Full Text] [Related]
16. Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.
Qian J; Chen Y; Meng T; Ma L; Meng L; Wang X; Yu T; Zask A; Shen J; Yu K
Oncotarget; 2016 Oct; 7(41):67071-67086. PubMed ID: 27563814
[TBL] [Abstract][Full Text] [Related]
17. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
18. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
19. TIS21 (/BTG2/PC3) as a link between ageing and cancer: cell cycle regulator and endogenous cell death molecule.
Lim IK
J Cancer Res Clin Oncol; 2006 Jul; 132(7):417-26. PubMed ID: 16456675
[TBL] [Abstract][Full Text] [Related]
20. Selective activation of Akt1 by mammalian target of rapamycin complex 2 regulates cancer cell migration, invasion, and metastasis.
Kim EK; Yun SJ; Ha JM; Kim YW; Jin IH; Yun J; Shin HK; Song SH; Kim JH; Lee JS; Kim CD; Bae SS
Oncogene; 2011 Jun; 30(26):2954-63. PubMed ID: 21339740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
